modelA10BH03

Diagram of A10BH03

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Saxagliptin
ATC code:A10BH03
route:oral
compartments:2
dosage:5mg
volume of distribution:105L
clearance:13.3L/h
other parameters in model implementation

Saxagliptin is an oral antidiabetic medication used for the treatment of type 2 diabetes mellitus. It is a selective inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme, which increases incretin levels (GLP-1 and GIP), inhibiting glucagon release and increasing insulin secretion. Saxagliptin is approved and widely used today as a second-line therapy for glycemic control.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult human subjects, both male and female, following a single oral 5 mg dose under fasting conditions.

References

  1. Boulton, DW, et al., & Lacreta, F (2013). Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. British journal of clinical pharmacology 75(3) 763–768. DOI:10.1111/j.1365-2125.2012.04391.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22823746

  2. Li, H, et al., & Zhao, J (2012). Pharmacokinetic study of saxagliptin in healthy Chinese subjects. Clinical drug investigation 32(7) 465–473. DOI:10.2165/11598760-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22668067

  3. Scheen, AJ (2015). Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clinical pharmacokinetics 54(1) 1–21. DOI:10.1007/s40262-014-0198-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25331711

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)